MXPA02000021A - Metodos y composiciones para la sintesis de peptidos. - Google Patents
Metodos y composiciones para la sintesis de peptidos.Info
- Publication number
- MXPA02000021A MXPA02000021A MXPA02000021A MXPA02000021A MXPA02000021A MX PA02000021 A MXPA02000021 A MX PA02000021A MX PA02000021 A MXPA02000021 A MX PA02000021A MX PA02000021 A MXPA02000021 A MX PA02000021A MX PA02000021 A MXPA02000021 A MX PA02000021A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- group
- peptide
- polypeptide
- protected
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 84
- 238000010647 peptide synthesis reaction Methods 0.000 title claims description 10
- 239000000203 mixture Substances 0.000 title description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 155
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 119
- 239000012634 fragment Substances 0.000 claims abstract description 61
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 41
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 39
- 239000007790 solid phase Substances 0.000 claims abstract description 21
- 102000007079 Peptide Fragments Human genes 0.000 claims abstract description 20
- 108010033276 Peptide Fragments Proteins 0.000 claims abstract description 19
- 229920001184 polypeptide Polymers 0.000 claims description 69
- 125000006239 protecting group Chemical group 0.000 claims description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- -1 t-butyloxycarbonyl Chemical group 0.000 claims description 18
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 16
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- 125000003368 amide group Chemical group 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- 125000004185 ester group Chemical group 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 claims description 4
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- OBSIQMZKFXFYLV-QMMMGPOBSA-N L-phenylalanine amide Chemical compound NC(=O)[C@@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 claims description 2
- ZFEAMMNVDPDEGE-LGRGJMMZSA-N tifuvirtide Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(C)=O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 ZFEAMMNVDPDEGE-LGRGJMMZSA-N 0.000 abstract description 78
- 239000000543 intermediate Substances 0.000 abstract description 28
- 239000007791 liquid phase Substances 0.000 abstract description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 123
- 239000011347 resin Substances 0.000 description 74
- 229920005989 resin Polymers 0.000 description 74
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 70
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 66
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 54
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 150000001413 amino acids Chemical group 0.000 description 37
- 239000000243 solution Substances 0.000 description 36
- 229940024606 amino acid Drugs 0.000 description 33
- 235000001014 amino acid Nutrition 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 19
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 238000010168 coupling process Methods 0.000 description 12
- 238000002386 leaching Methods 0.000 description 12
- 238000010532 solid phase synthesis reaction Methods 0.000 description 12
- 125000000539 amino acid group Chemical group 0.000 description 11
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 9
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 5
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 108010037251 peptide T1249 Proteins 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 239000012317 TBTU Substances 0.000 description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000005587 bubbling Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000003930 superacid Substances 0.000 description 4
- 238000003828 vacuum filtration Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229940113088 dimethylacetamide Drugs 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000003880 polar aprotic solvent Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 2
- MGHMWKZOLAAOTD-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1h-indol-3-yl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)NC(C(=O)O)CC1=CNC2=CC=CC=C12 MGHMWKZOLAAOTD-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 238000010268 HPLC based assay Methods 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000027326 copulation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000012508 resin bead Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- LXAVCFDWHMZCJH-UHFFFAOYSA-N 2-[4-(hydroxymethyl)-3-methoxyphenoxy]butanoic acid Chemical compound CCC(C(O)=O)OC1=CC=C(CO)C(OC)=C1 LXAVCFDWHMZCJH-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZYASLTYCYTYKFC-UHFFFAOYSA-N 9-methylidenefluorene Chemical compound C1=CC=C2C(=C)C3=CC=CC=C3C2=C1 ZYASLTYCYTYKFC-UHFFFAOYSA-N 0.000 description 1
- 241000132092 Aster Species 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000490229 Eucephalus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010072476 SIV envelope protein gp41 Proteins 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical class CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- PMJARSVDFGNNRI-UHFFFAOYSA-N dichloromethane;piperidine Chemical compound ClCCl.C1CCNCC1 PMJARSVDFGNNRI-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-M lysinate Chemical compound NCCCCC(N)C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-M 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- OARVXDFNTLYMCJ-JVUUKAHWSA-N n-[(2r,3r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-[6-(naphthalen-1-ylmethylamino)purin-9-yl]oxolan-3-yl]-3,5-dimethoxybenzamide Chemical compound COC1=CC(OC)=CC(C(=O)N[C@H]2[C@@H](O[C@H](CO)[C@H]2O)N2C3=NC=NC(NCC=4C5=CC=CC=C5C=CC=4)=C3N=C2)=C1 OARVXDFNTLYMCJ-JVUUKAHWSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/349,205 US6469136B1 (en) | 1999-07-07 | 1999-07-07 | Methods and composition for peptide synthesis |
| PCT/US2000/035725 WO2001034635A2 (en) | 1999-07-07 | 2000-07-05 | Methods and compositions for peptide synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02000021A true MXPA02000021A (es) | 2002-07-02 |
Family
ID=23371340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02000021A MXPA02000021A (es) | 1999-07-07 | 2000-07-05 | Metodos y composiciones para la sintesis de peptidos. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6469136B1 (https=) |
| EP (1) | EP1372686B1 (https=) |
| JP (1) | JP2003530311A (https=) |
| KR (1) | KR100631874B1 (https=) |
| CN (1) | CN1267449C (https=) |
| AR (1) | AR024686A1 (https=) |
| AT (1) | ATE288278T1 (https=) |
| AU (1) | AU4133701A (https=) |
| BR (1) | BR0012249A (https=) |
| CA (1) | CA2378086A1 (https=) |
| DE (1) | DE60017955T2 (https=) |
| DK (1) | DK1372686T3 (https=) |
| ES (1) | ES2236043T3 (https=) |
| MX (1) | MXPA02000021A (https=) |
| PT (1) | PT1372686E (https=) |
| TW (1) | TWI237640B (https=) |
| WO (1) | WO2001034635A2 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6656906B1 (en) * | 1998-05-20 | 2003-12-02 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| WO2004013165A1 (en) * | 2002-07-24 | 2004-02-12 | F. Hoffmann-La Roche Ag | Pegylated t1249 polypeptide |
| US20040158037A1 (en) * | 2003-02-12 | 2004-08-12 | Bohling James Charles | Amino acid loaded trityl alcohol resins, method of production of amino acid loaded trityl alcohol resins and biologically active substances and therapeutics produced therewith |
| AU2004200485A1 (en) * | 2003-02-25 | 2004-09-09 | Rohm And Haas Company | Method of manufacturing T-20 and T-1249 peptides at commercial scale, and T-20 and T-1249 compositions related thereto |
| PL2298347T3 (pl) * | 2003-05-06 | 2016-03-31 | Bioverativ Therapeutics Inc | Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| WO2005063792A2 (en) * | 2003-12-31 | 2005-07-14 | F. Hoffmann-La Roche Ag | Methods for recovering cleaved peptide from a support |
| EP1701976A2 (en) * | 2003-12-31 | 2006-09-20 | F.Hoffmann-La Roche Ag | Peptide synthesis and deprotection with co-solvent |
| WO2005063800A2 (en) * | 2003-12-31 | 2005-07-14 | F. Hoffmann-La Roche Ag | Peptide synthesis using decanting filter |
| ATE376556T1 (de) * | 2003-12-31 | 2007-11-15 | Hoffmann La Roche | Verfahren zur peptidsynthese unter verwendung einer reduzierten menge an entschützungsmittel |
| ATE410437T1 (de) * | 2003-12-31 | 2008-10-15 | Hoffmann La Roche | Verfahren und systeme zur rückgewinnung von peptiden |
| KR101276422B1 (ko) * | 2004-03-15 | 2013-06-19 | 넥타르 테라퓨틱스 | Ｈｉｖ 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트 |
| ES2329270T3 (es) * | 2004-12-30 | 2009-11-24 | F. Hoffmann-La Roche Ag | Sintesis del peptido t-1249 utilizando fragmentos intermediarios del ipeptido. |
| JP4886702B2 (ja) * | 2004-12-30 | 2012-02-29 | エフ．ホフマン−ラ ロシュ アーゲー | ペプチド中間体断片を使用するペプチドｔ−２０の合成 |
| WO2006069779A1 (en) * | 2004-12-30 | 2006-07-06 | F. Hoffmann-La Roche Ag | Preparing of peptides with excellent solubility |
| WO2006069697A1 (en) * | 2004-12-30 | 2006-07-06 | F. Hoffmann-La Roche Ag | Colorimetrically assessing peptide characteristics |
| WO2006105199A2 (en) * | 2005-03-30 | 2006-10-05 | Trimeris, Inc. | Compositions and methods for synthesis of peptide and related conjugate |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| CA2651070A1 (en) | 2006-05-03 | 2007-11-15 | Mallinckrodt Inc. | Composition and method for the release of protected peptides from a resin |
| CN101195653B (zh) * | 2006-12-08 | 2010-05-12 | 吉尔生化（上海）有限公司 | 亮丙瑞林的固液合成法 |
| TW200911289A (en) * | 2007-08-09 | 2009-03-16 | Syntonix Pharmaceuticals Inc | Immunomodulatory peptides |
| CN101874038A (zh) * | 2007-09-25 | 2010-10-27 | 特里梅里斯公司 | 治疗性抗-hiv肽的合成方法 |
| CN101835794A (zh) * | 2007-10-27 | 2010-09-15 | 霍夫曼-拉罗奇有限公司 | 使用固相和溶液相组合技术的促胰岛素肽合成法 |
| EP2222695A2 (en) * | 2007-12-11 | 2010-09-01 | F. Hoffmann-La Roche AG | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
| WO2010014909A1 (en) * | 2008-08-01 | 2010-02-04 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
| TW201217527A (en) | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Processable single chain molecules and polypeptides made using same |
| CN102268065A (zh) * | 2011-06-23 | 2011-12-07 | 成都圣诺科技发展有限公司 | 氨基保护丝氨酸寡肽及其制备方法和用途 |
| CN102603869B (zh) * | 2012-03-27 | 2013-03-27 | 西安华澳丽康生物工程有限公司 | 六胜肽的合成方法 |
| WO2014144549A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Factor ix polypeptide formulations |
| US10450343B2 (en) | 2013-03-21 | 2019-10-22 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
| CA2907454C (en) | 2013-03-21 | 2021-05-04 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| CN108572171A (zh) * | 2017-03-10 | 2018-09-25 | 江苏金斯瑞生物科技有限公司 | 一种检测哌啶残留的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100358209B1 (ko) | 1992-07-20 | 2003-01-24 | 듀크 유니버시티 | Hiv복제를저해하는조성물 |
| JP3401005B2 (ja) | 1992-12-11 | 2003-04-28 | ユニバーシティ オブ フロリダ | 有害生物の防除のための材料および方法 |
| WO1994028929A1 (en) | 1993-06-07 | 1994-12-22 | Genentech, Inc. | Hiv envelope polypeptides |
| US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| WO1999048513A1 (en) * | 1998-03-23 | 1999-09-30 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
| US6258782B1 (en) * | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| US6217666B1 (en) | 1998-08-31 | 2001-04-17 | Danieli Technology, Inc. | Countercurrent reduction of oxides on moving metal |
-
1999
- 1999-07-07 US US09/349,205 patent/US6469136B1/en not_active Expired - Fee Related
-
2000
- 2000-07-05 AU AU41337/01A patent/AU4133701A/en not_active Abandoned
- 2000-07-05 DE DE60017955T patent/DE60017955T2/de not_active Expired - Fee Related
- 2000-07-05 CA CA002378086A patent/CA2378086A1/en not_active Abandoned
- 2000-07-05 PT PT00992116T patent/PT1372686E/pt unknown
- 2000-07-05 BR BR0012249-1A patent/BR0012249A/pt not_active IP Right Cessation
- 2000-07-05 AT AT00992116T patent/ATE288278T1/de not_active IP Right Cessation
- 2000-07-05 WO PCT/US2000/035725 patent/WO2001034635A2/en not_active Ceased
- 2000-07-05 KR KR1020027000199A patent/KR100631874B1/ko not_active Expired - Fee Related
- 2000-07-05 ES ES00992116T patent/ES2236043T3/es not_active Expired - Lifetime
- 2000-07-05 DK DK00992116T patent/DK1372686T3/da active
- 2000-07-05 MX MXPA02000021A patent/MXPA02000021A/es active IP Right Grant
- 2000-07-05 CN CNB008125309A patent/CN1267449C/zh not_active Expired - Fee Related
- 2000-07-05 EP EP00992116A patent/EP1372686B1/en not_active Expired - Lifetime
- 2000-07-05 JP JP2001537346A patent/JP2003530311A/ja not_active Ceased
- 2000-07-07 AR ARP000103508A patent/AR024686A1/es active IP Right Grant
- 2000-08-05 TW TW089113543A patent/TWI237640B/zh active
-
2002
- 2002-03-29 US US10/109,748 patent/US6767993B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU4133701A (en) | 2001-06-06 |
| ES2236043T3 (es) | 2005-07-16 |
| CN1267449C (zh) | 2006-08-02 |
| EP1372686B1 (en) | 2005-02-02 |
| CN1450906A (zh) | 2003-10-22 |
| JP2003530311A (ja) | 2003-10-14 |
| TWI237640B (en) | 2005-08-11 |
| EP1372686A4 (en) | 2004-01-02 |
| US6767993B2 (en) | 2004-07-27 |
| KR100631874B1 (ko) | 2006-10-09 |
| KR20020038676A (ko) | 2002-05-23 |
| US6469136B1 (en) | 2002-10-22 |
| DK1372686T3 (da) | 2005-05-30 |
| PT1372686E (pt) | 2005-05-31 |
| WO2001034635A3 (en) | 2003-10-16 |
| DE60017955T2 (de) | 2006-01-12 |
| BR0012249A (pt) | 2003-11-11 |
| WO2001034635A9 (en) | 2002-08-01 |
| US20030125516A1 (en) | 2003-07-03 |
| CA2378086A1 (en) | 2001-05-17 |
| WO2001034635A2 (en) | 2001-05-17 |
| DE60017955D1 (de) | 2005-03-10 |
| AR024686A1 (es) | 2002-10-23 |
| EP1372686A2 (en) | 2004-01-02 |
| ATE288278T1 (de) | 2005-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02000021A (es) | Metodos y composiciones para la sintesis de peptidos. | |
| US6281331B1 (en) | Methods and compositions for peptide synthesis | |
| AU751358B2 (en) | Methods and compositions for peptide synthesis | |
| EP1833843B1 (en) | Synthesis of peptide t-20 using peptide intermediate fragments | |
| EP1960423B1 (en) | Synthesis of peptide t-20 using peptide intermediate fragments | |
| CN101133076B (zh) | 使用肽中间片段合成肽t-1249 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |